|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 162.43 USD | -0.76% |
|
-2.73% | -4.45% |
| 01-13 | Jazz Pharmaceuticals plc Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 11:15 AM | |
| 01-12 | Jazz Pharmaceuticals plc - Expects to meet 2025 revenue guidance - SEC filing | RE |
| Capitalization | 9.87B 8.48B 7.91B 7.35B 13.71B 891B 14.79B 90.93B 35.73B 426B 37.01B 36.26B 1,571B | P/E ratio 2025 * |
-25.3x | P/E ratio 2026 * | 22x |
|---|---|---|---|---|---|
| Enterprise value | 13.19B 11.33B 10.57B 9.82B 18.32B 1,191B 19.76B 121B 47.74B 569B 49.46B 48.44B 2,099B | EV / Sales 2025 * |
3.12x | EV / Sales 2026 * | 2.73x |
| Free-Float |
97.06% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Jazz Pharmaceuticals plc
| 1 day | -0.76% | ||
| 1 week | -2.73% | ||
| Current month | -4.45% | ||
| 1 month | -3.03% | ||
| 3 months | +20.19% | ||
| 6 months | +47.30% | ||
| Current year | -4.45% |
| 1 week | 156.95 |  | 171.05 |
| 1 month | 156.95 | | 175.8 |
| Current year | 156.95 | | 175.8 |
| 1 year | 95.49 | | 182.99 |
| 3 years | 95.49 | | 182.99 |
| 5 years | 95.49 | | 189 |
| 10 years | 86.88 | | 189 |
| Manager | Title | Age | Since |
|---|---|---|---|
Renée Galá
CEO | Chief Executive Officer | 54 | 10/08/2025 |
Philip Johnson
DFI | Director of Finance/CFO | 61 | 29/02/2024 |
Liz Henderson
CTO | Chief Tech/Sci/R&D Officer | 54 | 31/07/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Cozadd
CHM | Chairman | 62 | 24/10/2019 |
Seamus Mulligan
BRD | Director/Board Member | 65 | 17/01/2012 |
Rick Winningham
BRD | Director/Board Member | 66 | 31/12/2009 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -4.03% | 14.47% | 303 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.76% | -2.73% | +31.89% | +3.81% | 9.87B | |
| -0.35% | +1.24% | +35.07% | +197.88% | 964B | |
| +1.87% | +4.33% | +47.89% | +23.19% | 515B | |
| +0.32% | -1.42% | +24.90% | +43.72% | 390B | |
| +1.10% | +2.19% | +31.21% | +17.31% | 363B | |
| +2.28% | +0.80% | +34.88% | +22.80% | 292B | |
| +1.36% | +1.83% | +28.38% | +34.17% | 272B | |
| -0.85% | -0.56% | +7.21% | -3.55% | 269B | |
| -0.44% | +4.28% | -35.49% | -19.79% | 265B | |
| -0.38% | -1.78% | +20.03% | +19.35% | 175B | |
| Average | +0.36% | +0.94% | +22.60% | +33.89% | 351.49B | |
| Weighted average by Cap. | +0.42% | +1.55% | +26.67% | +68.08% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 4.23B 3.63B 3.39B 3.15B 5.87B 382B 6.33B 38.95B 15.31B 182B 15.86B 15.53B 673B | 4.5B 3.86B 3.6B 3.35B 6.25B 406B 6.73B 41.41B 16.27B 194B 16.86B 16.51B 716B |
| Net income | -380M -327M -305M -283M -528M -34.34B -570M -3.5B -1.38B -16.41B -1.43B -1.4B -60.52B | 502M 431M 402M 374M 697M 45.34B 752M 4.62B 1.82B 21.67B 1.88B 1.84B 79.9B |
| Net Debt | 3.32B 2.85B 2.66B 2.47B 4.61B 300B 4.97B 30.57B 12.01B 143B 12.44B 12.19B 528B | 2.41B 2.07B 1.93B 1.79B 3.35B 218B 3.61B 22.2B 8.72B 104B 9.04B 8.85B 384B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/01/26 | 162.43 $ | -0.76% | 1,036,279 |
| 12/01/26 | 163.68 $ | +1.58% | 903,498 |
| 09/01/26 | 161.13 $ | +0.55% | 1,222,635 |
| 08/01/26 | 160.25 $ | -5.38% | 2,342,849 |
| 07/01/26 | 169.37 $ | +1.43% | 1,655,564 |
Delayed Quote Nasdaq, January 13, 2026 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- JAZZ Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition